Floatz logo

L-Carnitine L-Tartrate

Parkinson Disease

Istanbul Medipol University HospitalPhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
65/ 100

Competitive context

166 Active assets in the Parkinson Disease cohort.

Asset / SponsorPhaseRating
Ropinirole
Titan Pharmaceuticals
Phase 4BBB
Benserazide
Ankara Ataturk Sanatorium Training and Research Hospital
Phase 4BBB
Ongentys
Bial - Portela C S.A.
Phase 4BBB
Ctc-501
First Affiliated Hospital of Zhejiang University
Phase 4BBB
LEVODOPA
McMaster University
Phase 4BBB

View all 50 →

Same molecule, other indications

L-Carnitine L-Tartrate is also rated in:

chemotherapy-induced toxicityDormant
B
Indicative ·
60 / 100
View asset →
toxic encephalopathyDormant
B
Indicative ·
60 / 100
View asset →
Non-alcoholic Fatty Liver Disease (NAFLD)Dormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →